Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.63 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL1007041 | 1.00 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28558704 | 0.95 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8904329 | 0.95 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28912532 | 0.95 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Tyrosine SCHEMBL25286397 | 0.94 | SLC7A5 (0.60) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL26918992 | 0.94 | SLC7A5 (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28504393 | 0.91 | SLC7A5 (0.52) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL14631617 | 0.91 | SLC7A5 (0.52) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28894081 | 0.91 | SLC7A5 (0.52) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL7686784 | 0.91 | SLC7A5 (0.52) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785952-B | Light-sensitive peptide element for fluorescent sensing material, preparation method of light-sensitive peptide element, fluorescent sensing material, preparation method of fluorescent sensing material and application of fluorescent sensing material | 北京工商大学 | 2023-08-18 | — | — | CN | claimed |
| CN-116031036-A | Fluorescent peptide-loaded magnetic nanomaterial and preparation method and application thereof | 北京工商大学 | 2023-04-28 | — | — | CN | claimed |
| CN-115785952-A | Photosensitive peptide element for fluorescent sensing material and preparation method thereof, fluorescent sensing material and preparation method and application thereof | 北京工商大学 | 2023-03-14 | — | — | CN | claimed |
| CN-112007155-B | Photothermal immune nanofiber, and preparation method and application thereof | 中科南京绿色制造产业创新研究院（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-110734073-B | Preparation method of gel factor attapulgite assembled inorganic gel with double network structures | 中国科学院兰州化学物理研究所 | 2021-11-19 | — | — | CN | claimed |
| CN-112641956-A | Preparation and application of peptide-metal-drug self-assembly nanoparticles for resisting Alzheimer's disease | 福州大学 | 2021-04-13 | — | — | CN | claimed |
| CN-112007155-A | Photothermal immune nanofiber, and preparation method and application thereof | 中科院过程工程研究所南京绿色制造产业创新研究院 | 2020-12-01 | — | — | CN | claimed |
| CN-110734073-A | Preparation method of gel factor attapulgite assembled inorganic gel with double network structures | 中国科学院兰州化学物理研究所盱眙凹土应用技术研发中心 | 2020-01-31 | — | — | CN | claimed |
| EP-1888069-B1 | ANTIPROLIFERATIVE DRUG | EURAND PHARMACEUTICALS LTD (IE) | 2009-12-02 | — | — | EP | claimed |
| EP-1620122-A4 | USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL | REGEN BIOTECH INC (KR) | 2009-08-12 | — | — | EP | claimed |
| CN-101227906-A | Antiproliferative drug | EURAND PHARMACEUTICALS LTD (IE) | 2008-07-23 | — | — | CN | claimed |
| EP-1888069-A2 | NEW ANTIPROLIFERATIVE DRUG | Eurand Pharmaceuticals Ltd (IE) | 2008-02-20 | — | — | EP | claimed |
| US-20070004622-A1 | Imidazole derivative, process for producing the same, and use | REGEN BIOTECH, INC. (KR) | 2007-01-04 | — | — | US | claimed |
| WO-2006122954-A2 | ANTIPROLIFERATIVE CONJUGATES COMPRISING HYALURONIC ACID AND N-DERIVATIVES OF GLUTAMIC ACID | EURAND PHARMACEUTICALS LIMITED (IE) | 2006-11-23 | — | — | WO | claimed |
| EP-1620122-A1 | USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL | Regen Biotech Inc. (KR) | 2006-02-01 | — | — | EP | claimed |
| US-20050244939-A1 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | AJINOMOTO CO., INC. (JP) | 2005-11-03 | — | — | US | claimed |
| WO-2004087193-A1 | USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL | REGEN BIOTECH INC.. (KR) | 2004-10-14 | — | — | WO | claimed |
| US-20030187049-A1 | Compositions based on aminoacids, suitable for improving muscle performance | PROFESSIONAL DIETETICS SRL (IT) | 2003-10-02 | — | — | US | claimed |
| US-20020052486-A1 | Nucleotide sequences which code for the gpmB gene | DEGUSSA AG (DE) | 2002-05-02 | — | — | US | claimed |
| EP-0324227-A1 | A composition of matter for increasing intracellular atp levels and physical performance levels and for increasing the rate of wound repair | Roncari, Raymond A. (US) | 1989-07-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050244939-A1 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | ALDOA, MON2, HOGA1 | SLC7A5 2198/4885ALPI 720/4885PKM 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.